Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 4/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 6/20 | 0.41 |
| ▸ | CCKAR | P32238 | 1/20 | 0.41 |
| ▸ | CCKBR | P32239 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 3/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5926476 | 0.91 | ACLY (0.52) | CTSAKCNA5CYP26A1CCKARCCKBR | |
| SCHEMBL5927111 | 0.89 | ACLY (0.52) | CTSAKCNA5CYP26A1CCKARCCKBR | |
| SCHEMBL8339983 | 0.85 | CCKAR (0.54) | CCKARCCKBR | |
| SCHEMBL5926353 | 0.85 | CCKAR (0.54) | CCKARCCKBR | |
| SCHEMBL5926580 | 0.84 | KCNA5 (0.47) | CTSAKCNA5CYP26A1ACLYMMP12 | |
| SCHEMBL5926538 | 0.84 | ACLY (0.50) | KCNA5ACLY | |
| SCHEMBL5926378 | 0.83 | KCNA5 (0.47) | CTSAKCNA5MMP3MMP9MMP13 | |
| SCHEMBL5926687 | 0.82 | KCNA5 (0.49) | KCNA5CYP26A1ACLY | |
| SCHEMBL5926310 | 0.80 | METAP2 (0.49) | CTSAKCNA5 | |
| SCHEMBL6098358 | 0.80 | METAP2 (0.49) | CTSAKCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | CTSA 426/4885KCNA5 1021/4885CYP26A1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.